Draft:Jun12682

From WikiProjectMed
Jump to navigation Jump to search

Jun12682
Clinical data
Other namesHY-157403, CS-0915641, XB5
Routes of
administration		By mouth
Identifiers
  • 5-[2-(dimethylamino)ethoxy]-N-[(1R)-1-[3-(1-ethylpyrazol-3-yl)-5-(1-methylpyrazol-4-yl)phenyl]ethyl]-2-methylbenzamide
PubChem CID
Chemical and physical data
FormulaC29H36N6O2
Molar mass500.647 g·mol−1
3D model (JSmol)
  • CCN1C=CC(=N1)C2=CC(=CC(=C2)[C@@H](C)NC(=O)C3=C(C=CC(=C3)OCCN(C)C)C)C4=CN(N=C4)C
  • InChI=1S/C29H36N6O2/c1-7-35-11-10-28(32-35)24-15-22(14-23(16-24)25-18-30-34(6)19-25)21(3)31-29(36)27-17-26(9-8-20(27)2)37-13-12-33(4)5/h8-11,14-19,21H,7,12-13H2,1-6H3,(H,31,36)/t21-/m1/s1
  • Key:ZOMNORZQANASQP-OAQYLSRUSA-N

Jun12682 is an experimental antiviral medication being studied as a potential treatment for COVID-19. It is believed to work by inhibiting the SARS-CoV-2 papain-like protease (PLpro).[1][2]

References

  1. ^ Tan B, Zhang X, Ansari A, Jadhav P, Tan H, Li K, Chopra A, Ford A, Chi X, Ruiz FX, Arnold E, Deng X, Wang J (March 2024). "Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model". Science. 383 (6690): 1434–1440. doi:10.1126/science.adm9724. PMID 38547259.
  2. ^ "Researchers racing to develop Paxlovid replacement". ScienceDaily. 24 March 2024. Retrieved 8 July 2024.
Retrieved from "https://mdwiki.org/wiki/Draft:Jun12682"